Processa Pharmaceuticals Inc (NASDAQ: PCSA)’s stock price has increased by 0.56 compared to its previous closing price of 0.59. However, the company has seen a -15.51% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2025-01-27 that HANOVER, MD, Jan. 27, 2025 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced the pricing of its “reasonable best efforts” public offering with participation from the Company’s Chief Executive Officer, certain board members, and existing institutional investors of the Company, along with a healthcare focused institutional investor, consisting of 8,050,672 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying Series A warrants to purchase up to 8,050,672 shares of common stock (or pre-funded warrants in lieu thereof) and Series B warrants to purchase up to 4,025,336 shares of common stock at a combined purchase price per share (and accompanying warrants) of $0.615 for the institutional investors and $0.7975 for the Company’s Chief Executive Officer and certain board members.
Is It Worth Investing in Processa Pharmaceuticals Inc (NASDAQ: PCSA) Right Now?
The stock has a 36-month beta value of 0.54. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PCSA is 3.34M, and at present, short sellers hold a 2.59% of that float. On January 30, 2025, the average trading volume of PCSA was 345.07K shares.
PCSA’s Market Performance
The stock of Processa Pharmaceuticals Inc (PCSA) has seen a -15.51% decrease in the past week, with a -38.11% drop in the past month, and a -54.79% fall in the past quarter. The volatility ratio for the week is 15.80%, and the volatility levels for the past 30 days are at 10.88% for PCSA. The simple moving average for the past 20 days is -26.50% for PCSA’s stock, with a -59.01% simple moving average for the past 200 days.
Analysts’ Opinion of PCSA
Many brokerage firms have already submitted their reports for PCSA stocks, with H.C. Wainwright repeating the rating for PCSA by listing it as a “Buy.” The predicted price for PCSA in the upcoming period, according to H.C. Wainwright is $8 based on the research report published on April 25, 2024 of the previous year 2024.
PCSA Trading at -36.46% from the 50-Day Moving Average
After a stumble in the market that brought PCSA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.08% of loss for the given period.
Volatility was left at 10.88%, however, over the last 30 days, the volatility rate increased by 15.80%, as shares sank -34.91% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -44.64% lower at present.
During the last 5 trading sessions, PCSA fell by -15.51%, which changed the moving average for the period of 200-days by -66.35% in comparison to the 20-day moving average, which settled at $0.8058. In addition, Processa Pharmaceuticals Inc saw -32.98% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PCSA starting from Ng George K, who purchase 87,200 shares at the price of $0.80 back on Jan 27 ’25. After this action, Ng George K now owns 87,200 shares of Processa Pharmaceuticals Inc, valued at $69,542 using the latest closing price.
Young David, the Pres. Research & Development of Processa Pharmaceuticals Inc, purchase 124,500 shares at $0.80 during a trade that took place back on Jan 27 ’25, which means that Young David is holding 205,405 shares at $99,289 based on the most recent closing price.
Stock Fundamentals for PCSA
The total capital return value is set at -3.92. Equity return is now at value -211.71, with -176.99 for asset returns.
Based on Processa Pharmaceuticals Inc (PCSA), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -114.84. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -3.48.
Currently, EBITDA for the company is -11.46 million with net debt to EBITDA at 0.24. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.97.
Conclusion
To sum up, Processa Pharmaceuticals Inc (PCSA) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.